Pacer Advisors Inc. Has $1.46 Million Position in Insulet Co. (NASDAQ:PODD)

Pacer Advisors Inc. cut its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 14.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,609 shares of the medical instruments supplier's stock after selling 921 shares during the quarter. Pacer Advisors Inc.'s holdings in Insulet were worth $1,464,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Baillie Gifford & Co. raised its holdings in Insulet by 20.7% during the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier's stock valued at $529,669,000 after acquiring an additional 389,639 shares during the period. Geode Capital Management LLC raised its stake in shares of Insulet by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier's stock valued at $403,339,000 after purchasing an additional 22,850 shares during the period. Westfield Capital Management Co. LP raised its stake in shares of Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock valued at $175,697,000 after purchasing an additional 163,388 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Insulet by 43.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier's stock worth $148,091,000 after purchasing an additional 193,839 shares during the period. Finally, Fisher Asset Management LLC boosted its position in shares of Insulet by 0.9% in the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier's stock valued at $81,719,000 after acquiring an additional 3,113 shares during the period.

Insider Buying and Selling at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Lauren Budden sold 915 shares of the business's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PODD. TD Cowen upped their price target on shares of Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, January 3rd. Canaccord Genuity Group raised their price target on Insulet from $269.00 to $304.00 and gave the company a "buy" rating in a report on Monday, December 9th. Citigroup boosted their price objective on Insulet from $283.00 to $310.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. JPMorgan Chase & Co. raised their target price on shares of Insulet from $280.00 to $330.00 and gave the company an "overweight" rating in a research note on Thursday, December 12th. Finally, Morgan Stanley increased their price target on shares of Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a report on Monday, November 11th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $277.13.

Insulet Price Performance

NASDAQ PODD traded up $2.97 on Thursday, hitting $287.67. The company had a trading volume of 501,113 shares, compared to its average volume of 535,205. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $288.05. The company has a market capitalization of $20.18 billion, a PE ratio of 49.26, a PEG ratio of 3.49 and a beta of 1.23. The company's fifty day moving average price is $269.95 and its 200-day moving average price is $240.32.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The business had revenue of $543.90 million during the quarter, compared to analysts' expectations of $518.50 million. During the same quarter in the prior year, the company posted $0.71 EPS. As a group, analysts predict that Insulet Co. will post 3.22 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.